Premier Alternatives

Sunbird Bio

Cambridge, MA · Founded 2020 · Privately Held (backing)

Developer of a diagnostics platform designed to provide fast and accurate results in molecular diagnostics. Sunbird Bio is based in Cambridge, MA and was founded in 2020. Its last reported valuation was $16 million in Nov 2022. It has raised $27.3 million across 1 recorded round; the latest was a $23.2 million early-stage round in Apr 2023.

Last reported valuation
$16.0M
Oct 2026
Priced at
—
Total raised
$27.3M
Last round
Early Stage VC
Apr 2023

Sunbird Bio key facts

as of Oct 2026
  • Developer of a diagnostics platform designed to provide fast and accurate results in molecular diagnostics.
  • Sunbird Bio is valued at approximately $16.0M as of Oct 2026 (last reported valuation).
  • It has raised $27.3M across 1 recorded rounds; the latest was Early Stage VC ($23.2M) in Apr 2023.
  • Notable investors include Alumni Ventures, EDBI, ARCH Venture Partners, S32, Polaris Partners — 11 tracked in total.
  • Sunbird Bio has filed 1 Form D with the SEC, most recently May 2023 ($23.2M sold to 10 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$16.0M

Sunbird Bio's last reported valuation, Nov 2022. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Private Market View
More of Sunbird Bio with a free Private Market View account
  • ·The complete investor list: 11 names
  • ·Watch Sunbird Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Sunbird Bio funding rounds

1 rounds
Apr 2023Early Stage VC$23.2MSEC filing▮
Full funding history →

Sunbird Bio valuation

Sunbird Bio's last reported valuation was $16 million in Nov 2022. No priced round, secondary trade or fund mark has surfaced since.

How much has Sunbird Bio raised?

Sunbird Bio has raised $27.3 million across 1 recorded round since 2023. The largest was a $23.2 million early-stage round in Apr 2023.

Sunbird Bio has filed 1 Form D with the SEC, most recently in May 2023 ($23.2 million sold to 10 investors).

Sunbird Bio investors

11 investors are on record for Sunbird Bio, including Alumni Ventures, EDBI, ARCH Venture Partners and S32. By type, the record holds 6 venture capital firms and 1 family office. The early-stage round in Apr 2023 drew 10 investors.

About Sunbird Bio

Developer of a diagnostics platform designed to provide fast and accurate results in molecular diagnostics. The company's platform specializes in the detection of a wide range of diseases, which include infectious diseases, neurodegenerative diseases, and cancer, which can be diagnosed early, enabling physicians to improve lives by providing clarity and accessibility in diagnostic testing to better inform healthcare decisions and outcomes.

Sector
Healthcare
HQ
Cambridge, MA, United States
Founded
2020
Employees
32
Ownership
Privately Held (backing)

Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.